基于微藻的肠道小的向多阶段生物系统,用于刺激性肠道综合征治疗
Jiahui Ye1,2,3,4, Haimeng Sun3,4, Qing Zhang3,4
1Eye Center, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, P. R. China.
Nature communications
|August 15, 2025
概括
这项研究引入了一种新的微藻生物系统,用于刺激性肠综合征 (IBS) 治疗. 工程微藻增强药物输送和肠道健康,解决IBS的复杂性.
科学领域:
- 生物技术是生物技术.
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 刺激性肠综合征 (IBS) 是一种慢性疾病,影响肠-大脑轴.
- 目前的IBS治疗缺乏有效性和特异性,没有可用的向药物.
- 在IBS中患者的药理动力学参数因胃肠道运动障碍而显著改变.
研究的目的:
- 开发一种口腔工程微藻生物系统,用于增强刺激性肠综合征 (IBS) 治疗.
- 为了克服IBS患者的药理动力学挑战,而不是通过传统的肠膜囊来解决问题.
- 为了利用微藻的益生菌潜力,改善IBS管理.
主要方法:
- 微藻与myricetin纳米颗粒的整合,以创建一个口腔生物系统.
- 工程微藻的培养和微纳米转化.
- 对微藻粘附于肠的评估,胃酸耐药性,以及对短链脂肪酸的影响.
主要成果:
- 工程微藻显示了对肠道的增强粘附性和对胃酸的抵抗性.
- 生物系统有效地解决了IBS中的药理学并发症.
- 微藻类表现出益生菌效应,增加短链脂肪酸水平.
结论:
- 工程微藻-瑞纳米粒子生物系统为IBS提供了一个新的治疗策略.
- 这种方法增强了药物输送,并通过肠-大脑轴向多器官症状.
- 生物系统显示了通过调节肠道微生物群和宿主生理学来改善IBS管理的潜力.
相关概念视频
Irritable Bowel Syndrome I: Introduction
382
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
382
Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
420
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
420
Drugs for Treatment of Constipation-Predominant IBS
333
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
333
Irritable Bowel Syndrome III: Medical and Nursing Management
302
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
302
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
245
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
245


